<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5C257E4C-2119-4EFF-9F6A-8EDA94878021"><gtr:id>5C257E4C-2119-4EFF-9F6A-8EDA94878021</gtr:id><gtr:name>Quethera Limited</gtr:name><gtr:address><gtr:line1>CAMBURGH HOUSE 27 , NEW DOVER ROAD</gtr:line1><gtr:city>CANTERBURY</gtr:city><gtr:postCode>CT1 3DN</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5C257E4C-2119-4EFF-9F6A-8EDA94878021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>5C257E4C-2119-4EFF-9F6A-8EDA94878021</gtr:id><gtr:name>Quethera Limited</gtr:name><gtr:address><gtr:line1>CAMBURGH HOUSE 27 , NEW DOVER ROAD</gtr:line1><gtr:city>CANTERBURY</gtr:city><gtr:postCode>CT1 3DN</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>5000.0</gtr:offerGrant><gtr:projectCost>5000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=753192"><gtr:id>D55E7E34-FA89-4F4A-89B6-E8947BE27BAE</gtr:id><gtr:title>Glaucoma patent advice</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Vouchers</gtr:grantCategory><gtr:grantReference>753192</gtr:grantReference><gtr:abstractText>Quethera is a Cambridge University gene-therapy spin-out company specialising in glaucoma neuroprotective therapies which are aimed at prevention of sight loss in high risk patients. The company is currently in the early stages of investigating a novel product concept, partly based on the known pathology which has been shown to play a major role in loss of retinal cells in the eye. Using proven and safe gene therapy technology, Quethera is aiming to advance the glaucoma therapy into clinical trials within three years which is designed to correct the pathology within the retina, thereby preventing blindness.</gtr:abstractText><gtr:fund><gtr:end>2016-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>5000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">753192</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>